Site search
2811 results for '' found
A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or refractory follicular lymphoma (NCT05888493)
A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or refractory follicular lymphoma (NCT05888493)
/
A Phase 3, Multicenter, Multinational, Open-label Extension Study to Evaluate the Long-term safety of CC-93538 in Adult and adolescent subjects with eosinophilic esophagitis. (NCT04991935)
A Phase 3, Multicenter, Multinational, Open-label Extension Study to Evaluate the Long-term safety of CC-93538 in Adult and adolescent subjects with eosinophilic esophagitis. (NCT04991935)
/
A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subject
A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subject
/
Study of using Cyclophosphamide After Sibling-donor allogeneic stem-cell Transplantation (CAST) in patients with acute leukaemia and myelodysplasia: a randomised study comparing cyclosporin and m
Study of using Cyclophosphamide After Sibling-donor allogeneic stem-cell Transplantation (CAST) in patients with acute leukaemia and myelodysplasia: a randomised study comparing cyclosporin and m
/
Colchicine After Stroke to Prevent Event Recurrence (CASPER) A randomised trial to evaluate the efficacy of oral Colchicine in high-risk patients with atherosclerosis-associated inflammation post
Colchicine After Stroke to Prevent Event Recurrence (CASPER) A randomised trial to evaluate the efficacy of oral Colchicine in high-risk patients with atherosclerosis-associated inflammation post
/
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BC
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BC
/
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexameth
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexameth
/
Concentrated Albumin infusion Prior to Rescue Infliximab (CAPRI) in steroid refractory Acute Severe Ulcerative Colitis (ASUC), a randomized clinical trial (ACTRN12619001081101p)
Concentrated Albumin infusion Prior to Rescue Infliximab (CAPRI) in steroid refractory Acute Severe Ulcerative Colitis (ASUC), a randomized clinical trial (ACTRN12619001081101p)
/
CAPLA trial: Catheter Ablation for persistent atrial fibrillation: A Multicentre randomised trial of Pulmonary vein isolation (PVI) vs PVI with posterior Left Atrial wall isolation (PWI) (ACTRN12
CAPLA trial: Catheter Ablation for persistent atrial fibrillation: A Multicentre randomised trial of Pulmonary vein isolation (PVI) vs PVI with posterior Left Atrial wall isolation (PWI) (ACTRN12
/
Catheter Ablation versus Medical Rate Control of Atrial Fibrillation in Patients with Systolic Heart Failure and Myocardial Fibrosis - An MRI Guided Multi-Centre Randomised Controlled Trial (CAME
Catheter Ablation versus Medical Rate Control of Atrial Fibrillation in Patients with Systolic Heart Failure and Myocardial Fibrosis - An MRI Guided Multi-Centre Randomised Controlled Trial (CAME
/